At the BIO International Convention 2026, clinical-stage generative AI drug discovery company Insilico Medicine announced a record-breaking $2.5 billion global R&D collaboration with SK Biopharmaceuticals to develop central nervous system treatments, alon (IMAGE)

InSilico Medicine

At the BIO International Convention 2026, clinical-stage generative AI drug discovery company Insilico Medicine announced a record-breaking $2.5 billion global R&D collaboration with SK Biopharmaceuticals to develop central nervous system treatments, alon

Caption

At the BIO International Convention 2026, clinical-stage generative AI drug discovery company Insilico Medicine announced a record-breaking $2.5 billion global R&D collaboration with SK Biopharmaceuticals to develop central nervous system treatments, alongside driving extensive thought leadership across five featured presentations.

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.